Bolster_Marcy_Boston_web.jpg Take drug, patient-level factors into account for when to end antiresorptive therapy LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy. Metz_David_PHILA_web.jpg PPI-fracture link can’t be ruled out PHILADELPHIA – While observational studies provide some evidence of a modest association, a randomized trial published this month showed a lack of PPI effect on bone homeostasis in healthy, postmenopausal women. Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching. Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions “The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.
